We read with interest the report from Pavlů and colleagues [1] in which they showed that, in patients with myeloma, the haematological recovery following a second autograft after high-dose melphalan was similar to that after the first autograft when a single mobilisation procedure had been performed and the apheresis product split equally, with one aliquot being used for the first autograft and one for the second. The median interval between infusion of the first and the second half of the harvest was 4.0 (range 2.3-9.6) years and the authors interpreted this as showing there was no loss of progenitor cell potency during the storage in vapour-phase liquid nitrogen. However, it should be noted that significantly more patients received a reduced dose of melphalan (25/50) for the second autograft than prior to the first (9/50) (P = 0.0007), which might potentially influence the recovery times. We present similar data in 22 patients with myeloma at our own institution. Importantly, only two of our patients received a reduced dose of melphalan with the second procedure because of perceived frailty and storage was in a −140°C mechanical freezer. The median time between transplants was 3.9 (range 1.7-7.5) years. The median time to neutrophil and platelet recovery after the first autograft was 12 and 11 days, respectively and 11 and 10 days after the second procedure (Table 1 ). In no case was the time to neutrophil recovery >1 day greater than the time to recovery following the first transplant.
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Our data thus supports the conclusion of Pavlů et al. [1] that stem cells do not lose potency during storage at either −170 or −140°C and that the analysis of recovery after split harvest autografts serves as a valuable quality assurance parameter.
Furthermore, the data indicate that the marrow microenvironment has not been damaged, at least with respect to the support of early haematological recovery, by the highdose melphalan and any chemotherapy given to the patient between the procedures. Testa and colleagues [2] demonstrated over 30 years ago that chemotherapy and irradiation could cause lasting damage to the murine bone marrow including the microenvironment as assessed by colonyforming units (CFU)-fibroblast assays, and del Cañizo and colleagues [3] assessed haematopoietic damage 1 year after autologous peripheral blood stem cell transplant and showed a reduced generation of CFU-granulocyte macrophages in long-term bone marrow cultures due to damage in both the progenitor and stromal cell compartments. However, any such damage does not appear to impede early haematological recovery, at least after high-dose melphalan and any intervening drugs used in the treatment of myeloma. Use of split peripheral blood stem cell harvests
